- Home
- VTGN vs SCYX Comparison
VTGN vs SCYX Comparison
Compare VTGN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | SCYX |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 32.6M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VTGN | SCYX |
|---|---|---|
| Price | $0.61 | $0.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $0.90 | ★ $3.00 |
| AVG Volume (30 Days) | ★ 736.7K | 328.6K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | $124.49 | $90.24 |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.57 |
| 52 Week High | $5.14 | $1.29 |
Technical Indicators
Market Signals| Indicator | VTGN | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 62.21 |
| Support Level | $0.50 | $0.69 |
| Resistance Level | $0.65 | $0.88 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 54.55 | 72.97 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.